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THE INTERACTION OF WNT-11 AND SIGNALLING CASCADES IN 
PROSTATE CANCER 
Sarah Koushyar 
Abstract 
Castration resistant prostate cancer proposes an array of issues in terms of 
treatment options.  It is therefore necessary to decipher the underlying mechanism 
involved in androgen independent prostate cancer and neuroendocrine 
differentiation, which is associated with malignant and metastatic disease.  Wnt-11 
has been previously shown to be associated with the more malignant version of the 
disease by being involved in the cellular proliferation and differentiation of the 
cancerous cells.  The methodology adopted to identify signalling pathways 
triggered upon Wnt-11 activation were inhibition of the JNK, PKA, PI3K and 
mTOR pathway with various concentrations of inhibitors, proceeding this 
proliferation, migration and gene expression experiments were carried out three 
times, each experiment containing a triplet of each condition.  Results collected 
were significant in all experiments excluding the proliferation results involving the 
PKA pathway.  A preliminary mechanism was established between Wnt-11 and the 
mentioned pathways with neuroendocrine differentiation. The experiments carried 
out along with the correlated data were novel and brings research one step closer 
to understanding the mechanism of androgen independent prostate cancer, which 
in turn can hopefully relay to new therapy options which are currently absent on 
the market.   
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Chapter one: Introduction 
Issues surrounding detection, management and prevention of prostate 
cancer have driven many debates amongst scientists across the world.   
The main objective for current prostate cancer (PCa) researchers is to 
define treatment options that are successful for both localised and 
metastatic disease.   
 The hot topic of prostate specific antigen (PSA) testing becoming legal 
within the UK still remains in question. According to the U.S. Food and 
Drug Adminstration, 4.0 ng/ml is described as the upper limit of PSA 
for PCa (Makarov et al., 2009). An increased PSA level although it can be 
indicative of PCa, can also be linked to benign prostatic hyperplasia, 
urinary tract infections and prostatitis. This leads to the assumption that 
the PSA test is more sensitive than specific.  On the other hand, the PSA 
test can neglect diagnosing PCa and cannot distinguish between 
aggressive and non-aggressive forms.  A modification to the PSA test 
includes monitoring the PSA levels over a period of time.  This is 
defined as PSA velocity, which is the change in PSA levels per year 
(ng/ml/year). There is therefore a need for more reliable biomarkers to 
generate more efficient and effective methods to screen and monitor the 
progression of PCa. An example of a biomarker that has been well 
characterized in PCa is the chromosomal rearrangement namely, the 
TMPRSS2-ETS gene fusion. The TMPRSS2 gene is an androgen 
responsive promoter, which when fused with the transcriptional factor 
from the ETS family can drive tumour progression under androgen 
influences.  According to Makarov et al., (2009) this gene fusion was 
present in 79% of 29 PCa cases.  Although this biomarker has been 
statistically proven to be correlated with PCa, the time at which is 
presents itself it still unclear, (Makarov et al., 2009). 
 Nonetheless, PCa still remains a major health risk for men especially 
over the age of 65 and according to (Wilt and Ahmed, 2013) the yearly 
death rate owing by PCa is more than 100,000 cases.  
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1.1 Pathogenesis of prostate cancer 
Androgens are vital for the normal development of the prostate gland.   
Testosterone is primarily synthesised in the testes, however the adrenal 
gland also contributes to a small proportion of the total androgen 
amount. Androgens are metabolised by 5α-reductase, to 
dihydrotestosterone (DHT).  It is DHT, which acts as the ligand and 
binds to the androgen receptor (AR) with a 5 fold stronger affinity that 
receptor than testosterone. The androgen receptor belongs to the steroid 
receptor family, made of four domains; N-terminal domain, central 
DNA binding domain, the hinge region and the C-terminal ligand-
binding domain (Girling et al., 2007).  
Following interaction between AR and DHT, phosphorylation and 
homo-dimerisation of the AR occurs. The heat shock protein also 
dissociates from the AR, allowing the translocation of the AR towards 
the nucleus.   Within the nucleus are androgen response elements to 
which the AR binds promoting androgen sensitive gene transcription. 
For transcription to occur, two activation function domains are essential, 
namely AF-1 and AF-2 (Girling et al., 2007). The AR is unique in that the 
AF-1 domain can be activated in the absence of the hormone, which is 
supported by studies showing that hormone refractory cells were still 
activated with the presence of AF-1, even in the company of anti-
androgens (Girling et al., 2007). 
The term hormone independent PCa cells may be misleading, as it 
implies the AR is no longer essential for growth. However, statistics 
show that more than 80% of hormone refractory PCa tumours still 
express the AR, and it’s the AR overexpression in these cells that can be 
activated by adrenal androgens (Girling et al., 2007). It is this 
phenomenon that causes the substantial levels of DHT which still 
remain after surgical or medical castration in PCa patients.  Along with 
overexpression of the AR, over 70 point mutations have been identified 
in PCa tumours; these occur predominantly in the ligand binding domain 
(Girling et al., 2007). These mutations can therefore allow a multitude of 
non-specific ligands such as oestrogen and anti-androgens to activate the 
AR. This causes the downfall of anti-androgen therapies and accordingly 
more specific treatment measures need to be investigated.   
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For the transcriptional activity of the AR, both co-activators and co-
repressors are required. Upon ligand and AR interaction, the co-activator 
also binds to this complex; this causes the catalysis of histone acetyl-
transferase, allowing a more open chromatin structure.  This is essential 
for the transcriptional machinery to bind.  P300 and Tip60 are two 
known co-activators the AR, which have been said to be up-regulated 
during androgen ablation. This could account for the transition to 
hormone independence (Girling et al., 2007).   
The ligand independent androgen receptor activation is the main 
concern for PCa treatment. Activation of the AR without a ligand 
induces its phosphorylation and acetylation producing a conformational 
change followed by transactivation. The main pathways which have been 
said to be involved in this process are the mitogen activated protein 
kinase (MAPK) and the phosphoinositol 3-kinase (PI3K) pathways. 
Hormones such as insulin like growth factor (ILGF) and epidermal 
growth factor (EGF) can instigate both pathways. ILGF can cause AR 
activation with a similar amount as to DHT.  This may be due to the 
dephosphorylation of Serine 650 inhibiting AR nuclear transport (Girling 
et al., 2007). Additionally, the loss of the tumour suppressor gene PTEN, 
is associated with cancer relapse and the inability to response to 
androgen ablation.   
Interleukin 6 has also been studied, and can function to activate both 
MAPK and PI3K pathways, and its implications have been seen in PCa 
(Chang et al., 2014). Up-regulation of this extracellular protein was seen 
in both prostate tissue and patient serum of hormone refractory disease 
(Chang et al., 2014). 
PCa stem cells have been implicated in PCa pathogenesis. They have 
been described to be negative for the AR, incurring resistance to 
androgen ablation.  The survival mechanism of these stem cells allows 
them to proliferate causing an increase in tumour burden. The 
heterogeneity of cancer stem cells accounts for the different molecular 
characteristics of each individual tumour, therefore for successful 
treatment, the cancer stem cells need to be targeted. CD133 has been 
identified as a beneficial cancer stem cell marker, however the small 
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population of cancer stem cells limits the amount of marker profiling 
that can be carried out (Lawson et al., 2005). 
All the processes mentioned are unlikely to act independently and it’s the 
heterogeneity of PCa that leads one to assume it’s a multi-step process, 
involving multiple factors, which leads to the onset of PCa. 
1.2 Prostate cancer treatment 
The current treatments available on the market for PCa are suited mainly 
to the androgen dependent disease.  First active surveillance is an option 
for those who have no signs or symptoms and have an indolent cancer 
and most likely contained within the prostate gland. Chemotherapeutic 
agents approved for the treatments of PCa include Docetaxel, 
Prednisone and Cabazitaxel. The most common treatment for PCa is the 
use of androgen ablation.  This can take three forms.  Firstly the entire 
testicular region can be removed via surgery to remove the main bulk of 
the androgen production.  Secondly, anti-androgens can be administrated 
such as Flutamide and Bicalutamide, that bind to the AR, hold it in an 
inactive state and cause the recruitment of co-repressors, halting 
translation of androgen responsive genes.  Thirdly, Leutinizing hormone 
antagonists can be used which acts on the hypothalamus pituitary axis, 
preventing the stimulation of androgen production.  
 In terms of castration resistant, Abiraterone Acetate can be used which 
inhibits the CYP17 enzyme which is responsible for the production of 
androgens (Kenneth et al., 2009). Enzalutamide known as a hormone 
treatment blocks the signalling cascade which is activated once the 
androgen receptor is in contact with a ligand (Kenneth et al., 2009).   
1.3 Wnt proteins and their functions 
Embryogenesis and adult homeostasis are just two of the many functions 
that cysteine rich glycoproteins, also known as the Wnt proteins carry 
out. However when aberrant Wnt signalling occurs, tumourgenesis can 
arise, an example being PCa. Two Wnt signalling pathways have been 
identified, namely the canonical and non-canonical pathway. A hallmark 
of the canonical pathway is the activation and stabilisation of a signalling 
pool of β-catenin. This leads to the transcription of many cancer genes in 
the nucleus by binding to a number of transcriptional factors. The 
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regulation of β-catenin gene expression is mediated by interaction of 
Wnt with the frizzled receptor and the co-receptor low-density 
lipoprotein receptor related protein (LEF-1). β-catenin can then 
translocate to the nucleus with both T cell specific transcriptional factor 
and lymphoid enhancing binding factor-1 (TCF/LEF-1), which are both 
part of the transcriptional factor family, to regulate target genes such as c-
myc and c-jun.  In the absence of Wnt signalling, a low level of β-catenin 
in the cell is maintained by ubiquitination and degraded by the 
destruction complex.  The destruction complex constitutes adenomatous 
polyposis coli protein (APC), glycogen synthase kinase 3 β. (GSK3β), 
casein kinase 1 and finally the axin proteins. However, when initiation of 
Wnt signalling occurs, the destruction complex is inactivated thus 
accumulation of β-catenin occurs. This signalling pathway is 
demonstrated in the figure below. 
 
Figure 1: The inactive and active Wnt pathways. Image adopted from 
Abcam 2014. 
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1.4 Wnt-11 and prostate cancer 
Wnt-11 is one of the 19 known Wnt proteins and belongs to the non-
canonical signalling pathway, which involves initiation of other signalling 
cascades such as the planar cell polarity and the protein kinase C (PKC) 
pathway. In some cases, non-canonical pathways can antagonise the 
canonical pathway. The non-canonical pathway is less defined than the 
canonical pathway, thus more research is crucial.  
The more clearly defined non-canonical signalling pathway is the 
Wnt/planar cell polarity signalling. Wnt-11 interaction with the Frizzled 
receptor can activate Dishevelled (Dvl) which is a cytoplasmic scaffold 
protein to the plasma membrane.  This causes downstream signalling to 
occur which activates different features of cytoskeleton reorganisation in 
cell movement and polarity to occur. For example Daam1 and RhoA are 
activated which can lead to the activation of JNK (Wang, 2009).  The 
PCP signalling pathway has been implicated in the metastasis of cancer 
and the formation of angiogenesis, thus its importance weighs heavily in 
cancer research.  
The role of Wnt-11 in PCa is complex. For example, for cellular 
proliferation in tumours to occur androgens are essential, however 
androgens decrease Wnt-11 expression, yet a considerable amount of 
tumours still express high levels of Wnt-11 (Uysal-Onganer and Kypta, 
2012). This could be the result of the fusion gene TMPRSS2-ERG 
formation. With regards to other cell lines, Wnt-11 has been shown to 
increase the survival of MCF-7, breast cancer cells and Chinese hamster 
ovary cells (Uysal-Onganer et al., 2010). 
 According to Zhu et al., (2004), there is a positive correlation between 
the expression of Wnt-11 and the malignancy of the disease. It has been 
reported that numerous Wnt genes were expressed in both normal 
prostate cells and cancerous prostate cells indicating that these genes play 
a role in the ‘house-keeping’ of the prostate gland (Zhu et al., 2004). 
However it has been said that expression of Wnt-11 alone is not 
sufficient to progress PCa cells to androgen independence and therefore 
other aberrations alongside Wnt-11 expressions are needed for this 
phenomenon to occur. Numerous theories surround the fact that Wnt-
11 expression is increased in androgen-depleted LNCaP cells. For 
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example Wnt-11 may take part in the termination of cell growth 
following androgen depletion by the means of a signal produced by Wnt-
11. If this is the case, the specific signal has yet to be identified. Another 
theory is that the increase in Wnt-11 expression in androgen depleted 
LNCaP cells is due to their differentiation. Following on from this, 
research carried out by Uysal-Onganer et al., (2010) demonstrated that 
the transfection of LNCaP cells with Wnt-11 caused the morphology to 
undergo NED. 
1.5 Neuroendocrine differentiation (NED) 
Neuroendocrine cells constitute a population of cells found in the 
epithelial compartment of the prostate gland that are able to secrete 
factors to stimulate the survival and metastatic potential of cancerous 
prostate cells.  They partake in the differentiation and growth of 
epithelial cells in the presence of androgens.  The origin of cancerous 
NE cells still remains unknown however one theory states that they 
originate from the intermediate stem cells (Yuan et al., 2007).  Normal 
NE cells express cytokeratin 5, a basal cell marker.  On the other hand 
NE like cancer cells expresses prostatic acid phosphastase and K18, both 
markers of luminal secretary cells.  The current therapy of androgen 
ablation has been noted to increase the incidence of NED that is 
associated with poorer prognosis for PCa. As mentioned earlier, Wnt-11 
expression inactivates androgen receptor expression in LNCaP cells; 
grouping this information with the fact that NED also leads to a loss of 
androgen receptors, one can assume that Wnt-11, whilst promoting 
NED, diminishes the androgen receptor indirectly. However this 
information is only relevant to the LNCaP cell line. The function of 
Wnt-11 in the onset of NED has been said to be restricted to PCa cells 
only (Uysal-Onganer et al., 2010), as the ectopic expression of Wnt-11 in 
the RWPE-1 cell line, which is non-tumorigenic and exhibit 
characteristics similar to prostate progenitor cells, did not induce any 
NED. The commencement of NED is through a PKA dependent 
manner, thus the inhibition of this pathway theoretically should inhibit 
NED.  
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To summarise, Wnt-11 is involved in progression of PCa cells, migration 
into surrounding tissues and differentiation of these cells in neurone like 
cells.  
1.6 Wnt pathway antagonists 
Dickkopfs and sclerostin have been identified as inhibitors of the LRP 
co-receptor, meaning they are specific antagonists of the canonical 
pathway. Secreted molecules that inhibit both the canonical and non-
canonical pathways are the Wnt inhibitory factor and the secreted 
frizzled related protein which both bind to Wnt in the extracellular space 
(Kypta and Kawano, 2003). However recently, both molecules have been 
said to be not pure antagonists of the Wnt signalling, and can actually 
participate in receptor activation (Kypta and Kawano, 2003). 
1.7 Prostate cancer and the protein kinase C (PKC) 
pathway 
The binding of the Wnt ligand to the Frizzled (Fz) receptor leads to a 
sudden increase in the concentration of intracellular signalling molecules 
such as inositol 1,4,5-triphosphate (IP3), 1,2 diacylglycerol (DAG), and 
Ca2+. Both IP3 and DAG are resultants from the action of 
phospholipase C on the membrane bound phospholipid, phosphatidyl 
inositol 4,5-bisphosphate (Garg et al., 2012).  This results in the diffusion 
of IP3 through the cytosol towards the endoplasmic reticulum, where 
calcium channels are found causing a release of calcium ions.  Both 
DAG and calcium ions activate two calcium sensitive proteins PKC and 
calmodulin dependent kinase II (CamKII) which then activate nuclear 
transcription factors such as NFAT, NFκB and CREB that transcribe 
downstream regulatory genes.   As you can see, PKC is one of the main 
components of the non-canonical pathway involved in the Wnt/Ca2+ 
signalling and has been found to take part in promoting invasiveness and 
malignancy in human cancers (Garg et al., 2012). Using small hairpin 
RNA to disorder individual PKC isozymes both in vitro and in vivo 
experiments demonstrated that depending on cell types and signalling 
pathways, PKC isozymes are either pro-apoptotic or anti-apoptotic. It is 
noted that tumour cells display an altered balance in PKC isozyme 
expression. For example the isoform PKCϵ has been seen to be elevated 
in high grade prostate tumours and is involved in the progression of the 
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tumour and the transition from an androgen dependent state to an 
androgen-independent state in LnCaP cells (Garg et al., 2012). 
Interestingly, activation of JNK downstream of TNFβ was increased in 
PKCϵ depleted cells, whereas overexpression of PKCϵ decreased JNK 
activation, suggesting some kind of interlink between the two pathways. 
Therefore pharmacological targeting of PKCϵ within prostate tumours 
where PKCϵ is overexpressed can be a potential treatment.  
1.8 Prostate cancer and c-jun N-terminal kinases (JNK) 
pathway 
A member of the mitogen activated protein kinases (MAPKs) family is c-
jun N-terminal kinases (JNKs). MAPKs can activate a variety of 
processes including cellular proliferation, tumourgenesis, differentiation 
and apoptosis.  JNKs mode of action is to phosphorylate serine 63 and 
73 at the N-terminal domain of c-jun.   This in turn stimulates protein-1, 
which carries out transcriptional activity.  C-jun is essential for the 
transition of the G1 phase to the remainder of the cell cycle.  It also 
carries out a protective role against UV-induced apoptosis.  At present 
there are only three distinct spliced JNK genes, JNK1, JNK2 and JNK3. 
JNK3 is primarily expressed throughout the nervous system, as opposed 
to JNK1 and JNK2 which are ubiquitously expressed.  JNKs become 
activated during cellular stress due to exposure to UV, hypoxia, osmotic 
pressure and variation in cytokines and growth factors. Moreover, JNKs 
play a vital role in the inflammatory signalling network; therefore the 
hyper-activation of JNKs is not surprisingly associated with oncogenic 
transformation (Saadeddin et al., 2009).   
Reports indicate that less than an hour of JNKs activation relates to cell 
survival whereas more sustained activation of JNKs causes pro-apoptotic 
signalling.  Moreover JNK participates in mRNA stabilization, cell 
migration, and integrity of the cell skeleton (Saadeddin et al., 2009).  
Members of the JNK family are robustly involved in the regulation of 
certain transcriptional factors such as ATF2, stat3, c-myc and members 
of the Bcl-2 family. There is gathering evidence to show that JNK is 
involved in carcinogenesis and the blocking of JNK signalling with small 
molecule JNK inhibitors can be beneficial in the treatment of cancer. 
TGFβ-1 has been identified as a key activator of JNK1, which in turn 
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phosphorylates p21, a cell cycle regulator, and up-regulates its stability 
through a SMAD independent mechanism (Saadeddin et al., 2009).    
1.9 Prostate cancer and NFκB pathway 
There is gathering evidence that NF-κB has a key function in tumour 
progression and chemotherapy resistance. Its function is to regulate 
numerous cytokines such as TNF-β, IL-8 and IL-1, cell adhesion 
molecules such as VCAM and cell cycle genes such as c-myc and p53. 
Interestingly, it has been shown that NF-κB can regulate gene expression 
involved in cell motility and invasiveness, an example being MMP-9. The 
activation of NF-κB can take two pathways: classical or alternative. The 
classical pathway is triggered by either viral or bacterial infections. The 
alternative pathway is activated by the members of the tumour necrosis 
factor family (Garg et al., 2012). It has been reported that the isoform 
PKCϵ mediates the activation of NF-κB in PCa cell lines and there is an 
established correlation with the overexpression of PKCϵ and the 
constant activation of NF-κB in PCa cells. A transgenic PCa mouse 
model of PKCϵ overexpression triggered pre-neoplastic lesions with 
noteworthy hyper activation of NF-κB. With the use of interfering RNA 
(RNAi) targeting PKCϵ, the translocation of NF-κB to the nucleus was 
consequently depleted, impairing NF-κB transcription. Furthermore 
PKCϵ aids the assembly of the tumour necrosis receptor-1 signalling 
complex, which in turn activates NF-κB. Studies carried out by Garg et 
al., (2012), demonstrated a molecular link between NF-κB and PKCϵ 
which play a pivotal role in PCa progression.  On another note, the link 
between NF-κB expression and AP-1 in PCa cells may have something 
to do with the differences in sensitivity to TNF-induced apoptosis in 
PCa cell lines. To investigate, two cell lines were used: androgen 
dependent LNCaP cells and androgen independent DU145 cells. Results 
indicated that DU145 cells always expressed the activate form of NF-κB 
and AP-1, and thus were resistant to TNF induced apoptosis, whereas 
LNCaP cells were seen not to express NF-κB, and, therefore were 
susceptible to TNF induced apoptosis (Garg et al., 2012). 
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1.10 Prostate cancer and the cAMP/protein kinase A 
pathway 
Wnt11 has been reported to activate PKA and its interaction with cyclic 
AMP (cAMP). cAMP is a second messenger present in every cell and can 
direct a variety of functions such as cell growth, differentiation, ion 
channel activation, gene expression and apoptosis. The cAMP signalling 
pathway also interlinks with other intracellular signalling such as Ca2+ 
and Ras-mediated MAP kinase. cAMP best known mode of action is 
interaction with cAMP dependent protein kinases (PKA) (Caretta and 
Caretta, 2011). During pathological conditions such as PCa, the 
composition of the PKA holoenzyme or its localisation within the cell 
may change prompting abnormal effects. An important role of PKA is 
regulation of cellular proliferation by acting on transcriptional factors, an 
example being the prevention of the interaction between Ras and c-Raf, 
thus hindering its activation. The cAMP pathway is concurrent with Ras-
activation through a negative feedback loop involving phosphorylation 
of phosphodiesterases, which diminishes cAMP concentrations within 
cells (Caretta and Caretta, 2011).  
1.11 Prostate cancer and the Rho signalling pathway 
The family of Rho proteins regulate the transition between an active 
GTP bound and an inactive GDP bound conformation. Both Rho and 
Rac are the most studied members of this family with Rho regulating the 
assembly of actin and myosin filaments while Rac initiates the actin 
polymerisation at the periphery of the cell. Therefore one can say Rho-
GTPases are ideally positioned for non-canonical signalling such as the 
polarised reorganisation of the actin cytoskeleton, leading to cell 
movement. One of the best models providing genetic evidence for Rho 
GTPase participation in non-canonical Wnt signalling is in the 
organisation of the Drosophilia wing. In the wing, activation of the Fz 
receptor results in localised Rho activation. Alongside this, Rac activation 
by either the Fz receptor or Dsh causes JNK activation, initiating gene 
expression (Schlessinger et al., 2009). 
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1.12 Prostate cancer and the phosphoinositide 3-kinase 
(PI3K) pathway 
The phosphoinositide 3-kinase pathway plays a fundamental role in the 
initiation of malignancy and its progression. The initial signalling is 
activated by tyrosine kinase receptors or non-tyrosine kinase receptors’ 
interaction with a ligand that then goes onto engaging with PI3K. PI3K 
then proceeds to convert phosphatidylinositol (4,5)-bisphosphate (PIP2), 
which is membrane bound to phosphatidylinositol (3,5)-bisphosphate 
(PIP3). This in turn activates and phosphorylates Akt.   Akt translocates 
to the cytoplasm and nucleus, activating downstream targets (Sarker et al., 
2009). Akt has a multi-functional purpose in promoting cell survival 
regulating pathways that take part in the cell cycle, resistance to 
apoptosis, and interaction with a host of proteins including GSK3 
(glycogen synthase kinase 3) and mTOR (mammalian target of 
rapamycin). mTOR is a serine threonine kinase which is involved in 
cellular proliferation and cell growth (Roccaro et al., 2010).   There are 
two known functional complexes of mTOR, mTOR1 and mTOR2.  
mTOR1 is said to be rapamycin sensitive whereas mTOR2 is not.  
PTEN, (phosphatases and tensin homolog) a tumour suppressor gene, is 
an obligate negative regulator of the PI3K/AKT/mTOR signalling 
pathway and is a crucial therapeutic target for cancer when signalling 
cascades out of control.   Deregulation of this pathway can arise through 
a series of events.  These include loss of function of PTEN through 
mutation, gene deletion or epigenetic silencing or mutation of 
AKT/PKB (Sarker et al., 2009).   
In 42% of primary prostate tumours, mutation of the 
PI3K/AKT/mTOR signalling pathway and its altered expression has 
been reported (Bitting and Armstrong, 2013). Androgens have been 
reported to cause the accumulation of TORC2 complex components and 
stress-activated protein kinase interacting protein-1 in the nucleus.   This 
promotes the activation of AKT by TORC2 components. The loss of 
both Akt and PTEN is correlated with a poor clinical outcome for PCa 
patients, causing resistance to both chemotherapy and radiotherapy. 
Moreover, a loss of PTEN is associated with a raised Akt 
phosphorylation, and a higher Gleason grade. This can also promote 
castration resistant growth and a shorter time for metastasis to occur.  
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Furthermore, preclinical studies of the PI3K/AKT/mTOR pathway has 
highlighted its importance in maintaining the population of cancer stem 
cells population and promotes the transition of PCa cells from the 
epithelium to the mesenchymal (Bitting and Armstrong, 2013).    
The PI3K/AKT/mTOR pathway interacts with other signalling 
cascades such as androgen receptor signalling and the RAS/RAF/MEK 
signalling. The human epidermal growth factor 2/3 kinases (HER2/3) 
inhibit androgen receptor signalling through the PI3K/AKT/mTOR 
pathway through a negative feedback system.  Moreover, PTEN can 
enhance AR activity by supressing the transcription of c-jun and EGR1 
which inhibit AR transcription.  Therefore, one can say that the ability of 
PCa cells to survive in androgen deprived conditions is due to PTEN 
loss or the activation of the PI3K/AKT/mTOR pathway through 
targeted inhibition of the AR signalling.   
1.13 Aims 
 This thesis will focus on the role Wnt-11 signalling takes in the onset of 
PCa, its progression and its malignancy. In particular the focus will be 
identifying signals activated by Wnt-11; the mechanism of its 
downstream signal transduction cascades; their interactions with one 
another, and whether the inhibition of certain pathways will decrease 
cellular proliferation, migration and neuroendocrine differentiation 
(NED). This can translate to novel and effective treatment options that 
can be utilised in a clinical environment. 
1.14 Hypothesis 
 The hypothesis of this thesis is that targeting downstream signalling 
pathways of Wnt-11 such as the JNK, PKA, PI3K and mTOR pathway 
will have a negative effect on neuroendocrine differentiation, cell 
proliferation and migration. Thus providing a novel outlook on 
androgen independent prostate cancer treatment.  
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Chapter two: Methodology  
2.1 Cell culture 
PC-3 and LNCaP cell lines were both obtained from the American Type 
Culture Collection and were received as a gift from Imperial College 
London. Both PC-3 and LNCaP cell lines were maintained in RPMI 
1640 medium accompanied with 10% fetal bovine serum (FBS) 
(Invitrogen), 1% penicillin streptomycin supplemented with L-glutamine, 
and 1% amphotericin B.  Cell lines were grown in a Thermo Scientific 
incubator at 37°C with 5% CO2.  
2.2 Cell viability assays: MTT and SRB 
MTT, (3[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide 
assay); both cell lines were seeded in 24 well plates at 5 x 104 cells per 
well. Cells were left to seed for 24 hours and various inhibitors were 
added in triplicates. The plates were once again left for 24 hours with the 
inhibitors and a control.  The MTT solution concentration of 5mg per 
ml of PBS was filtered using a minisart high flow syringe filter.  50 μL of 
the MTT solution was added to each well and incubated for three hours. 
The media and solution was then removed and 400μL of DMSO was 
added to each well. The triplets were then transferred to a 96 well plate 
where the absorbance could be measured.  The optical density was 
measured at 570nm using a 96 well plate reader. 
SRB stain (Sulforhodamine B colormetric stain).  Similar to the MTT 
cells were seeded at a cell number of 5 x 104 cells per well in a 24 well 
plate.  100μL of trichloroacetic acid (TCA) was added to the existing 
media to fix the cells to the plate and incubated at 4°C for 1 hour.  The 
plate was then washed five times using tap water and oven dried until no 
standing moisture was seen.  The TCA stained cells were then stained 
with 100μL of the SRB stain for 1 hour on a shaking platform.  The dye 
was then washed three times with 1% acetic acid.  The cell bound dye 
was re-solubilised in 10mM of tris solution, 300μL per well.  Solutions 
were then transferred to a 96 well plate for the absorbance to be read at 
570nm using the plate reader.  
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2.3 Qualitative RT-PCR 
RNA was extracted from cells using Isolate RNA Mini Kit.  The purity 
and concentration of RNA (µg/µl) was measured using a nanodrop. The 
amount of RNA needed to give a concentration of 1µg/1µl was 
calculated and reverse transcribed using Qiagen One-step RT-PCR kit.  
2.4 cDNA Synthesis and PCR 
For neuroendocrine markers such as Neurogenin2, NeuroD1 and DDC the 
two step PCR method was adopted. The first step entailed using the 
BiolineTetro cDNA synthesis kit to create cDNA from various RNA 
samples. To amplify the desired DNA fragment the BiolineMyTaq Red 
DNA polymerase kit was used.  
2.5 Gel electrophoresis 
1% agarose gel was made with TAE buffer. 10µL of each sample was 
loaded with 2µL of loading buffer.  The ladder used was hyperladder 
100bp.  Samples were run at 70V for 30-45 minutes.  All negative blanks 
performed contained the buffer and water to show no contamination.  
2.6 Migration assay 
Cells were grown to a confluency of 80%-90% and trypsinised and re-
suspended in 10ml of 1% FBS RPMI medium. Cells were counted using 
a haemocytometer and 10 x 105 cells were plated onto a 8µm pore size 
PET tract-etched membrane insert in a 24 well plate.  The cluster well 
contained 1ml of 10% FBS RMPI with the upper chamber containing 
the cells and 500µL of 1% FBS RPMI.    After 12 hours of incubation, 
the filters were washed in 1ml of 1X PBS, dried and stained in 1ml of 
Hoechst solution for 15 minutes and then washed thoroughly with PBS.  
The membranes were cut with a scalpel and placed onto microscopes.  
20µL of DAPI loading buffer was added onto the membranes along with 
a cover slip.  Glass slides were then kept in cold conditions covered in 
foil.  Slides were examined using the Olympus fluorescence microscope.  
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2.7 Protein extraction 
Control cells and cells with various inhibitors were grown to a 
confluency of 80-90% and incubated for 24 hours. 10% RIPA buffer 
was made in cold PBS and 10% of phosphatase was added.  The cell 
culture dish was placed on ice and washed with ice cold PBS. The PBS 
was then drained and 1ml of the lysis buffer was added and kept on ice 
for 5 minutes.  The adherent cells were scraped using a plastic cell 
scraper and then gently the lysate was transferred to a microfuge tube.  
This was then centrifuged at 14000g at 4 degrees for 20 minutes.   
2.8 Inhibitors 
The inhibitor used for the JNK pathway was JNK VIII (Calbiochem) 
working concentration 10µM. Inhibitors used for the PKA pathway were 
H89 dihydrochloride (Sigma-Aldrich) and KT5720 (Sigma-Aldrich) 
working concentration 10µM. The inhibitor used for the PI3K pathway 
was Ly294002 hydrochloride (Sigma-Aldrich) working concentration 
1µM. The inhibitor used for the mTOR pathway was Rapamycin (Sigma-
Aldrich) working concentration 1µM. 
2.9 Statistical analysis 
All methods were independently repeated three times, each experiment 
entailed a triplet of each condition. Error bars represent the standard 
error of mean. A paired student t-test was performed on all results and 
significance was measured as a p value <0.05.   
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Chapter three: The effect of different pathways on 
prostate cancer cell proliferation, gene expression 
and migration 
3.1 Proliferation results for the PC-3 cell line 
To assess whether inhibitors of the PKA, PI3K, mTOR and JNK 
pathway had an effect on cellular proliferation, initially two methods 
were adopted; the SRB stain and MTT.  Table 1 presents the averaged 
normalised data over three experiments along with the standard 
deviation and standard error of mean for the SRB stain. Figure 2 
illustrates the accumulation of three experiments to gain an average for 
the optical density of PC-3 cells without any treatment, PC-3 cells with a 
10µM concentration of the PKA inhibitor KT5720 and PC-3 cells with 
10µM of JNK inhibitor JNK VIII.  Cells were plated at a cell number of 
5 x 104 for each assay.   
Conditions PC-3 no 
treatment 
PC-3 + 10µM 
of JNK VIII 
PC-3 + 10µM 
of KT5720 
Normalised 
value: 
1.00 0.78 0.8 
Standard 
deviation: 
0.05 0.05 0.09 
Standard error 
of mean: 
0.03 0.03 0.05 
Table 1: Normalised data collected for the SRB stain. Inhibitors used 
were JNK VIII for the JNK pathway and KT5720 for the PKA pathway. 
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Figure 2: Optical density obtained from the SRB assay. (n=3, KT5720 
20% reduction, p>0.05 ±0.05, JNK VIII 22% reduction ± 0.05). 
Data collected did not give a p value less than 0.05, therefore the data 
was not significant.  Therefore the SRB assay was changed to the MTT 
assay.  
However when the MTT assay was adopted and the averages from three 
independent experiments were collected, a higher decrease in optical 
density was seen between the control and the addition of inhibitors. 
Table 2 presents the averaged normalised data for the MTT assay. Figure 
3 illustrates the MTT data for the PC-3 cell line. 
Conditions: PC-3 no 
treatment 
PC-3 + 
10µM 
of Jnk 
VIII 
PC-3 + 
10µM of 
KT5720 
PC-3 + 
Rapamycin 
1µM 
PC-3 + 
Ly294002 
1µM 
Normalised 
value: 
1.00 0.6 0.7 0.61 0.47 
Standard 
deviation: 
0.07 0.15 0.13 0.107 0.05 
Standard 
error of 
mean: 
0.04 0.09 0.07 0.06 0.03 
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Table 2: Averaged normalised data collected for the MTT assay 
 
Figure 3: Optical density obtained from the MTT assay. N=3. (JNK 
VIII 40% reduction, p=0.02, ±0.09, KT 5720 30% reduction, p>0.05, 
±0.07, rapamycin 40% reduction, p=0.03 ±0.06, ly294002 50% 
reduction, p=0.0004 ±0.03). 
Figure 3 illustrates PC-3 cells plated at 5 x 104 cells under four 
conditions.  The first condition was PC-3 cells incubated with 10µM of 
JNK VIII for 24 hours.  This inhibitor gave a 40% reduction in PC-3 
proliferation with a p value of 0.02.  The next condition was PC-3 cells 
incubated with 10µM of the PKA inhibitor KT5720 that gave a 30% in 
PC-3 proliferation.  As the p value was greater than 0.05 this particular 
experiment was not significant.  The next condition was PC-3 cells 
incubated with 1µM of the mTOR inhibitor Rapamycin, which gave a 
40% reduction in PC-3 proliferation and had a highly significant P value 
of 0.03.  The final condition that gave the best decrease in PC-3 
proliferation was PC-3 incubated with 1µM of Ly294002 (p=0.0004). 
The MTT assay was also performed on the LNCaP cell line.  The 
inhibitor, which was not significant when compared to the normalised 
data of the PC-3 cell line, KT5920 was replaced with another PKA 
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inhibitor, H89 when used on the LNCaP cell line.  The table below 
presents the averaged normalised data collected for the MTT assay and 
the accompanying figure 4 illustrates the MTT results in a graph form. 
3.2 Proliferation results for the LNCaP cell line 
Conditions: LNCaP no 
treatment 
LNCaP 
+ 10µM 
of Jnk 
VIII 
LNCaP 
+ 10µM 
of H89 
LNCaP + 
Rapamycin 
1µM 
LNCaP 
+ 
Ly294002 
1µM 
Normalised 
value: 
1.00 0.6 0.57 0.39 0.31 
Standard 
deviation: 
0.26 0.14 0.13 0.07 0.08 
Standard 
error of 
mean: 
0.14 0.08 0.07 0.04 0.04 
Table 3: Averaged normalised data collected for the MTT assay on the 
LNCaP cell line. 
 
Figure 4: Optical density obtained from the MTT assay. N=3. (JNK 
VIII 32% reduction p value=0.003 ±0.08, H89 50% reduction, p 
value>0.05 ±0.07, Rapamycin 57% reduction, p value=0.01 ±0.04, 
Ly294002 72% reduction, p value=0.006 ±0.04). 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
lncap jnk* h89 rapamycin* ly29004*
O
p
ti
ca
l d
e
n
si
ty
 5
7
0
n
m
 
Conditions 
Optical density differences between LNCaP cell with 
no treatment and inhibitors 
25 | P a g e  
 
Figure 4 illustrates the normalised data collected for the LNCaP MTT 
assay assessing the effect each pathway had on the proliferation status of 
these cells.  First the JNK pathway inhibitor JNK VIII gave a 32% 
reduction in the LNCaP cell proliferation; this result was significant as 
the two-tailed t test provided a p value of 0.003.  Next the PKA inhibitor 
H89 gave 50% reduction in the cell proliferation, however the p value 
did not produce a value less than 0.05 therefore that experiment was not 
significant. Rapamycin produced a 57% reduction in the LNCaP cell 
proliferation and this was significant as the p value was 0.01.  Finally 
similarly to PC-3 cells, Ly294002 produced the best inhibition of LNCaP 
cell proliferation by 72% reduction with a p value of 0.006.  
 
The inhibitors screened and used for the PKA pathway were KT5720, 
H89, pki-(myr-14-22)-amide and RP-cAMPS. Both pki-(myr-14-22)-
amide and RP-cAMPS are not displayed in the graphs and an initial 
screening of pki-(myr-14-22)-amide and RP-cAMPS with the SRB stain 
provided an optical density higher than the control at the working 
concentration of 10µM.  The inhibitors used for the JNK pathway were 
JNK VIII and SP600, both used at a working concentration of 10µM. 
However SP600 did not give a significant reduction in optical density 
when compared to the control, therefore SP600 was not used in further 
experiments.  The inhibitors used for the PI3K pathway ly294002, 
working concentration 1µM and rapamycin for mTOR, working 
concentration 1µM.   
3.3 Gene expression in the PC-3 cell line 
As PCa cells have been previously shown to express high amounts of 
Wnt-11 and the NED marker, neurone specific enolase (NSE), the gene 
expression of both these were assessed in control cells and cells treated 
with the various inhibitors. Cells were grown to 80% confluency, 
incubated with inhibitors and the RNA was extracted.  The RNA was 
reversed transcribed using a one-step RT-PCR kit and the product was 
identified using gel electrophoresis. 
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Figure 5A-D:  RT-PCR gene expression in PC-3 cells. n=3.  
Figure 5A illustrates the gene expression of Wnt-11, NSE and Gapdh in 
PC-3 control cells however when 10µM of JNK VIII was incubated with 
the PC-3 cells for 24 hours the band for Wnt-11 and NSE is not seen. 
This suggests that the JNK pathway is involved in the mRNA expression 
of both NSE and Wnt-11.  Gadph is used as a control throughout the 
RT-PCR experiments to ensure the mRNA levels are constant in all 
conditions. Figure 5B illustrates that with the addition of 10µM of H89 
for 24 hours again the expression of both NSE and Wnt-11 is 
diminished.  The same applies for figure 5C whereby the addition of 
1µM of Ly294002 for 24 hours also diminishes the expression of both 
Wnt-11 and NSE.  Finally with regards to figure 5D Rapamycin was used 
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only to assess the expression of Wnt-11 and indeed it reduced the 
expression of Wnt-11 compared to the control.  These results do indeed 
suggest that the identified pathways do play a role in the expression of 
Wnt-11 and NSE. 
As targeting the PI3K pathway with Ly294002 has been successful for 
proliferation and gene expression analysis, a migration assay was taken 
forward.  
3.4 PI3K involvement in PC-3 cell migration 
The PC-3 cell line displays highly aggressive and metastatic 
characteristics, thus the approach to assess the involvement of the PI3K 
pathway in the migration of these cells was carried out. Initially 
experiments were carried out using various concentrations of ly294002 
until the appropriate concentration was found.  PC-3 cells were seeded at 
10 x 105 cells per well and incubated for 12 hours. Duplicate trans-well 
filters were assessed for each condition.  Analysis of the membranes with 
the fluorescence microscope included capturing 5 fields of view per 
membrane.  Cells in each field of view were counted and averaged.   
Preliminary results assessing the effect of 1µM of Ly294002 on the 
migrating PC-3 cells did not give a significant result, thus the 
concentration was increased to 2µM.   An average of three experiments 
was carried out. The final inhibitory effect on the migration of PC-3 cells 
with the addition of 2µM of ly294002 over a 12 hour incubation period 
was 78%. Figure 6 below illustrates three random fields of view of PC-3 
cells with no treatment and three random fields of view of PC-3 cells 
with 2µM of ly294002.  The pictures were taken using a fluorescent 
microscope at a magnification of 10X and DAPI.   
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Figure 6: PI3K inhibitor, Ly294002 reduced cell migration of PC-3 cells 
after 12h incubation by 78%.  Three random fields of view of migrating 
PC-3 cells for each condition were taken. The top three pictures show 
PC-3 cells with no treatment and the bottom three illustrates PC-3 cells 
incubated with 2µM of ly294002 for 12 hour. n=3.  
To assess the proliferative effect of ly294002 at 2µM, a MTT assay was 
repeated with the same cell number over a 12 hour incubation period.  
Figure 6 illustrates that the difference in proliferation over 12 hours with 
this inhibitor is not significant therefore an ideal candidate for inhibiting 
migrating PC-3 cells.  
 
Figure 7: Cellular proliferation of PC-3 cells over a 12 hour incubation. 
Results are not significant. Ly294002 (9.8% reduction ±0.08, n=3) 
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3.4 Gene expression of Wnt-11 in the LNCaP cell line 
Theory states that under normal conditions by which LNCaPs cells are 
cultured in 10% FBS RPMI, they do not express Wnt-11, as ectopic 
expression of Wnt-11 can halt their growth and differentiation. It is only 
when LNCaPs are serum starved for 24 hours or more; Wnt-11 
expression is up-regulated.  This is demonstrated in figure 8 below. 
 
 
 
 
 
  
Figure 8: Gene expression in serum starved LNCaP cells and PC-3 cells. 
n=3. 
3.5 Gene expression of Wnt-11 in the LNCaP cell line 
To assess further the involvement of the PKA, JNK and PI3K pathway 
in neuroendocrine differentiation, three neuroendocrine markers’ 
expression were assessed. The three markers are as follows; Neurogenin2, 
NeuroD1 and Dopa decarboxylase (DDC).   
Firstly the expression of Neurogenin2 in PC-3 cells with no treatment, 
PC-3 cells with 10µM of H89, PC-3 cells with 1µM of ly294002 and PC-
3 cells with 1µM of rapamycin was assessed.  The conditions of the cells 
were identical to previous experiments.  The only difference was that 
rather than the one-step PCR reaction kit, a two-step PCR was 
undertaken, first cDNA was synthesised then the PCR reaction took 
place. 
Figure 9 below illustrates the expression of NeuroD1 under the 4 
conditions.  
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Figure 9: Gene expression of NeuroD1 and Gapdh in PC-3 cells under 
4 conditions. n=3. 
One can depict that under normal conditions, PC-3 cells express the 
band for neuroD1, however when the inhibitors H89 and rapamycin are 
added the band is diminished.  On the other hand, it appears that the 
PI3K pathway inhibitor Ly294002 had no effect on inhibiting the 
expression of neuroD1.  
Figure 9 below illustrates the expression of Neurogenin2 under the 4 
conditions. 
 
 
 
 
 
 
Figure 10: Gene expression of Neurogenin2 and Gapdh in PC-3 cells 
under 4 conditions. n=3 
Figure 10 demonstrates that there is no difference in the expression of 
neurogenin2 in PC-3 cells under these four conditions. This may be due to 
the optimum conditions not being met, or perhaps these specific 
pathways are indeed not involved in the expression of this 
neuroendocrine marker.  
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Finally, the expression of DDC in PC-3 cells under the same conditions 
was assessed; the results are in the figure below. 
 
 
 
 
 
Figure 11:  Gene expression of DDC and Gapdh in PC-3 cells under 3 
conditions. n=3. 
Figure 11 shows the expression of DDC under three conditions, control 
PC-3 cells, PC-3 cells with 10µM of H89 and PC-3 cells with 1µM of 
rapamycin.  There is a notable reduction in the expression of DDC with 
the addition of both inhibitors, more so with the H89 inhibitor the PKA 
inhibitor, this agrees with multiply sources that the PKA pathway indeed 
plays a pivotal role in the onset of neuroendocrine differentiation.  
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Chapter Four: Discussion 
4.1 The interaction of Wnt-11 and signalling pathways 
The collected results throughout this thesis leads to the assumption there 
is a connection between the identified pathways, Wnt-11 and NED that 
is innovative and novel. The proposed mechanism is as follows; the 
activation of the PI3K pathway upon stimulation via tyrosine receptor 
kinases and non-receptor kinases leads to the dephosphorylation of 
GSK3β thus inhibiting its capacity to partake in the destruction complex 
that destabilises the accumulation of βcatenin.  As the definition between 
the non-canonical and the canonical pathway is rather disjointed one can 
then go on to say that this disruption of the destruction complex can 
initiate the interaction of Wnt-11 and its frizzled receptor.  This in turn 
can cause the downstream signalling of the PKA pathway.  Accordingly 
this leads to the onset of NED which numerous literatures supplement 
towards and also the resulted collected in this thesis.  Moreover, there is 
also documented evidence to suggest that both the PI3K and JNK 
pathway lead to the onset of NED. 
 
 
 
 
 
 
 
Figure 12: Schematic view of the involved pathways cross talk with 
Wnt-11 and NED. Red arrow = inhibition.  Green arrow= activation. 
Dotted arrow=unconfirmed.  
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This preliminary mechanism holds immense importance in unveiling the 
interaction and cross talk between the studied pathways, Wnt-11 and 
NED.  This could have the potential to stabilise a mechanism and can 
translate to targeting androgen-independent PCa, which at the moment 
has limited treatment options.   
4.2 JNK pathway and Proliferation and NED 
Figures 2-3 illustrate a significant difference in proliferation between the 
control PC-3 cells and PC-3 cells with10µM of JNK VIII in both cell 
lines.  In fact the p value for the LNCaP cell line experiment was more 
significant than the p value for the PC-3 cell line experiment.  It is well 
established that the JNK pathway is implicated in tumourgenesis as this 
data supports.  However as JNK has been implicated in both survival 
and apoptosis its function is still very convoluted.  The results collected 
in this thesis however highlight the importance of the JNK pathway in 
PCa survival as opposed to apoptosis. The theory to support this 
statement is that the activation of the JNK signalling cascade causes the 
transcription of members of the activating protein 1 (AP-1) 
transcriptional factor family such as c-jun, and junD.  It is these 
transcriptional factors that play a role in the proliferation of malignant 
cells.   According to (Das et al., 2011) knockout of JNK in murine 
embryo fibroblasts hindered the proliferation capacity of the cells, thus 
highlighting the JNK signalling pathway in proliferation.  This statement 
is in agreement with the in vitro experiments carried out in this thesis. 
What is interesting is that c-jun can interact with the AR enhancing its 
DNA binding ability.  This also gives an explanation to why the JNK 
pathway plays a role in PCa proliferation. A study carried out by (Chen et 
al., 2006) demonstrated that the over expression of a mutant c-jun 
caused an increase in gene expression, cell proliferation and androgen 
regulated AR transactivation in the LNCaP cell line.  Moreover over 
expression of si-RNA targeting c-jun diminished the growth of the 
LNCaPs.   Numerous studies, journals, papers and pharmaceutical 
studies provide evidence that the inhibition of the JNK signalling can 
benefit therapeutic therapies (Zhang et al., 2012).   Therefore the data 
collected regarding the involvement of JNK and PCa proliferation in this 
thesis is of high importance and can contribute to the developing studies.  
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Figure 5A illustrates that with the administration of 10µM of JNK VIII 
the expression of NSE is diminished in PC-3 cells.   It is known that 
taking on the characteristics of a neuroendocrine tumour, there is a vast 
amount of activator and inhibitory receptors that PCa cells will begin to 
express.  Therefore the activation of JNK by cytokine receptors may lead 
to the downstream event of NED.  To emphasis, the data collected also 
produces a theory that indeed the JNK pathway plays a role in the onset 
of NED, as this idea is novel it is of great importance to carry this 
information forward and to further assess the involvement of the JNK 
pathway in other neuroendocrine marker expression.  
4.3 The involvement of the PKA pathway in proliferation and NED 
Unfortunately, targeting the PKA pathway with two different inhibitors 
(KT5720 and H89) did not give significant results with regards to the 
LNCaP and PC-3 cell line.  The KT5720 inhibitor only gave a 30% 
reduction in proliferation in 24 hours in the PC-3 cells whereas H89 gave 
a 43% reduction in proliferation for the LNCaP cell line.   Perhaps it is 
merely a case the PKA pathway not being heavily involved in PCa 
proliferation.  On the other hand the concentration of both inhibitors 
(10µM) may not be optimum to produce a significant effect.    PKA 
possesses two regulatory and two catalytic subunits.  The regulatory 
subunits can be classified into 4 subtypes; RIalpha, RIbeta, RIIalpha and 
RIIbeta.  The expression of each subtype is dependent upon the cell type 
and environment. For example in prostate carcinoma, a rise in RIIbeta is 
associated with the inhibition of tumour growth whereas a rise in 
RIalpha can enhance cell proliferation (Caretta and Caretta).  Therefore 
the inhibitors used to target the PKA pathway may have targeted a 
regulatory unit which is not associated with PCa proliferation and was 
not present upon the time the experiment was carried out.  
The PKA pathway has been linked to NED, (Deeble et al., 2007) by the 
means of LNCaP cells acquiring neuroendocrine characteristics by 
increasing levels of cAMP by agents such as epinephrine and forskolin.  
More so, androgen ablation can incur an increase in intracellular cAMP.  
A study carried out by (Deeble et al., 2007) demonstrated that the 
addition of tetracycline to the LNCaP cell line caused a constant 
activation of PKA which lead to an enhanced neuroendocrine 
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morphology and secretion of neuropeptides.  Surprisingly, the serum 
starvation of LNCaP cells induced a 9-fold increase in cAMP levels and 
this could theoretically happen within a clinical environment with a 
patient undergoing androgen ablation, increasing the risk of NED.  All 
this information supports the results that figure 5B, 9 and 11 illustrate. 
As indeed once the PKA pathway was inhibited for 24 hours the 
expression of important neuroendocrine markers such as NSE, DDC 
and Neurogenin2 were reduced.  Interestingly there may be crosstalk 
between the JNK and PI3K pathways that all contribute to the complete 
onset of NED, which this thesis aimed to investigate and produced a 
preliminary novel mechanism. 
4.4 The involvement of the PI3K pathway, proliferation and NED 
By looking at figure 2 one can see that 1µM ly294002 the PI3K inhibitor 
had the leading effect on reducing the proliferation of PC-3 cells by 
50%.  This runs parallel for the LNCaP cell line by which the same 
inhibitor at the same concentration of 1µM inhibited the proliferation by 
70%.  The p value was highly significant for the PC-3 cell line (0.0004) 
and for the LNCaP cell line (0.006).  These results are completely backed 
up by numerous studies and have established that PI3K signalling 
partakes in several processes such as cancer progression and metabolism, 
survival, growth and motility.   Therefore this pathway is an ideal 
therapeutic target to inhibit these hallmarks of cancer.   In terms of 
isoforms of PI3K, Class 1A has been the most documented in 
carcinogenesis.  This isoform is activated by stimulation of growth 
factors through tyrosine kinase receptors or G-protein coupled 
receptors. It is this isoform; the inhibitor Ly294002 targets.  Therefore 
by targeting this isoform, stimulation of growth factors are inhibited 
inducing a haut in proliferation.   Moreover, the activation of PI3K along 
with mTOR activation phosphorylates and disables 4E-BP1, which is a 
repressor of mRNA translation and leads to the stimulation of S6K.  
According to (Arcaro and Guerreiro, 2007) Akt, which is a downstream 
target of PI3K induces the inhibition of tuberin-mediated degradation of 
p27.  This leads to an increase in CDK2 activity thus promoting cellular 
proliferation.  Moreover the PI3K pathway plays a role in the cell cycle 
entry by the means of inactivating FOXO genes results in the silencing of 
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quiescent genes such as p130 (Arcaro and Guerreiro, 2007).  FOXO 
genes and PI3K work in synergy, when PI3K is active, FOXO genes are 
inactivated and vice versa. This leads to a uniform regulation of the cell 
cycle.   Akt also initiates a signal allowing G1/S phase transition of the 
cell cycle.  For example Akt inactivates GSK3β causing downstream 
inhibition of tumour suppressor tuberin. Akt also employs anti-apoptotic 
activity by preventing cytochrome C release from mitochondria (Arcaro 
and Guerreiro, 2007).  Therefore mutant PI3K signalling can cause the 
constant activation of Akt, leading to a constant inactivation of tumour 
suppressor tuberin, leading to uncontrolled cell cycle progression and 
cellular proliferation.  Therefore by targeting this pathway one can 
disable disorderly cell proliferation that is shown in figures 3-4. 
Figure 5C illustrates that with the administration of 1µM of ly294002, the 
expression of NSE is diminished.  This complies with theory as 
according to (Wu and Huang, 2007) the PI3K pathway is essential for 
the NED phenomenon occurring in PCa.   The transition of androgen 
dependence to androgen independence is thought to have a connection 
with NED.  Studies support this theory include transgenic mouse models 
of PCa showing NED to be more prominent in poorly differentiated 
tumours and after castration.  It has been reported that LNCaPs as well 
as harbouring a point mutation in the PTEN gene, over expresses Akt 
upon androgen withdrawal.   Experiments carried out by (Wu and 
Huang, 2007) illustrated that by targeting key components of the PI3K 
pathway such as PI3K and mTOR with their respective inhibitors; 
ly294002 and rapamycin the expression of NSE was significantly 
reduced in serum starved LNCaP cells.  This correlates to data collected 
in the results chapter that show that the gene expression of NSE is 
reduced when 1µM of both ly294002 and rapamycin were added to PC-3 
cells.   
NE cells do not express the luminal marker of the androgen receptor.  
Thus with androgen ablation, these NE cells are able to escape therapy 
and begin paracrine networks leading to a proliferation increase, 
increasing tumour burden.  More so, NE cells have been shown to 
secrete IL-8 and the non-NE cells express the IL-8 receptor, (Sun et al., 
2009). Hence, there is a definite need to target these cells As this thesis 
has data to demonstrate certain pathways which leads to the onset of 
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NED, therapeutically targeting them could stop the NE cells escaping 
therapy and therefore preventing metastasis which could in turn give an 
improved prognosis for PCa patients.  
4.5 PI3K pathway and PC-3 cell migration 
Cancer metastasis is due to the migration capacity that cancerous cells 
undertake.  Therefore the idea of disabling the migration capacity of the 
PC-3 cells is an ideal target to prevent metastasis from the prostate 
gland.  Figure 6 indeed illustrates that the PI3K pathway plays a critical 
role in the migration of PC-3 cells through a trans-well filter.  This is 
demonstrated by the data analysis providing a 78% reduction in 
migrating PC-3 cells when 2µM of Ly294002 was administrated.   There 
is documented evidence that the PI3K pathway plays a direct role in 
migration as its activation can disorganise epithelial polarisation leading 
to migration.  It is the disturbance of this pathway that triggers actin 
structures alterations, stressing PI3K importance in cell motility.  
Activation of the PI3K pathway by intergrin initiates Rac activation.  Rac 
is part of the Rho GTPase family and the fate of each Rho GTPase 
function depends on two factors, tissue specificity and lipid 
modification.  Conferring to (Parri and Chiarugi, 2010), Rho proteins can 
regulate cell-to-cell adhesion, vesicle transportation, transcription and 
secretion of proteins.  In terms of the process of cell migration, Rac can 
initiate new actin polymerisation and is an essential component of the 
lamellipodium extension that is involved in the networking of actin 
filaments.  The PI3K pathway is key in initiating the Rac once this 
pathway is inhibited Rac activation is also blocked. These stresses the 
importance that PI3K should be targeted especially if it disables the 
migrating capacity of the highly aggressive PC-3 cells with a percentage 
as high as 78%.  
It has also been documented that Akt can promote the production of 
metalloproteinase -9 (MMP-9) from malignant cells thus aiding not only 
the migration capacity of these cells but their invasion capacity.  The 
PI3K pathway has not only been implicated in PCa, its role in migration 
has been recognised in breast cancer cell lines also.  For instant, a study 
demonstrated that PI3K is constantly active and regulates the cell 
motility of breast cancer cells by activating the transcriptional activity of 
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NF-κB, (Arcaro and Guerreiro, 2007).   Urokinase-type plasminogen 
activator (uPA) which has been shown to be strongly associated with 
cancer metastasis has a NF-κB binding site and it was exhibited that the 
extremely invasive MDA-MB-231 breast cancer cell line secreted copious 
amounts of uPA compared to the weakly invasive MCF-7 breast cancer 
cell line.  Moreover the blockade of the PI3K pathway weakened the 
migration of the cells and also reduced the amount of uPA.   There is 
increasing evidence that activation of NF-κB play a key role in the 
mechanism of tumourgenesis by protecting transformed cells from 
apoptosis.  An experiment carried out by (Huber et al., 2004) 
demonstrated that NF-κB along with oncogenic Ras can protect 
mammary epithelial cells from TNF-α initiated apoptosis and can induce 
epithelial to mesenchymal transition in the absence of TNF- α.  To sum 
up the PI3K pathway not only has been evidenced to play a role in the 
PC-3 cell migration, it also has been documented in other cancers such 
as breast cancer.  Therefore one can say that this pathway is key to be 
targeted in regards to migration and metastasis.   
4.6 The involvement of mTOR pathway and proliferation 
Rapamycin which targets mTOR1 had a vast effect on each cell line, 
40% reduction for the PC-3 cell line and 60% reduction for the LNCaP 
cell line which is shown in figures 2-3.  The reason to why rapamycin did 
not have the same effect on the proliferation as ly294002 is due to the 
difference in sensitivity to rapamycin between the two mTOR 
complexes, mTORC1 and mTORC2.  mTORC2 is known to be 
insensitive to rapamycin and there has yet to be an identified inhibitor to 
target this complex due to the functions of mTORC2 not being fully 
described (Feldman et al., 2009).  Theory states that mTORC2 is thought 
to control growth factor signalling by phosphorylation of Akt.   Akt is a 
key regulator in suppressing apoptosis and enhancing survival, thus the 
activation of mTORC2 may have the capacity to allow cellular 
proliferation and survival even in the presence of rapamycin. Upon 
administration rapamycin enters the cells and binds to its receptor 
FKB12, this complex then goes onto bind mTOR debilitating its 
function.   The mechanism behind the growth control through mTOR 
signalling begins with regulating the synthesis of proteins and silencing 
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autophagy, (Geurtin and Sabatini, 2005). A downstream target of 
rapamycin sensitive mTOR complex is S6K1 and is thought to run 
translation by phosphorylating S6, a ribosomal protein.  However it is 
not to say that the mTOR pathway does not play a role in the 
proliferation of PC-3 cells, as the p values were highly significant.  
Consequently dual therapy, which targets both the PI3K pathway and 
mTOR, may produce better-quality results in detaining both LNCaP and 
PC-3 cell proliferation.   
4.7 Neuroendocrine differentiation markers 
It is essential to identify improved neuroendocrine differentiation 
biomarkers within PCa to give a clearer view on the neuroendocrine 
phenotype, which is highly beneficial for the androgen independent 
disease. It can also be beneficial to assess tumour aggression and patient 
survival.  Inactivation of these neuroendocrine markers may be hugely 
beneficial for PCa therapy.  This thesis has focused on the expression of 
four main neuroendocrine markers; NSE which has already been 
covered, Neurogenin2, NeuroD1 and DDC.  
Firstly the expression of Neurogenin2 was assessed.  Figure 10 
demonstrates that control PC-3 do indeed expression Neurogenin2 
however with the administration of all the inhibitors there was no change 
seen in the mRNA expression.  This can indeed be accepted, as the 
expression of Gapdh was constant.  This data leads one to assume that 
the PKA, Ly294002 and mTOR pathway does not play a role in the 
expression of Neurogenin2. Perhaps under these conditions the 
concentration of each inhibitor was not optimum to produce a 
significant change in expression of this marker.  However as the JNK 
pathway was not assessed in this particular experiment, perhaps it would 
be an idea to evaluate the role JNK has in the expression of Neurogenin2.  
Second, the expression of NeuroD1 was also assessed.  Again, control 
PC-3 cells in 24 hours do indeed express NeuroD1, and with the addition 
of 10µM of the PKA inhibitor H89 the band has lessened.  On the other 
hand, with the addition of 1µM of Ly294002 the expression of NeuroD1 
does not change.  Perhaps indicating the PI3K pathway does not initiate 
the expression of NeuroD1.  Finally the expression of NeuroD1 is affected 
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by the administration of 1µM of rapamycin as the band is again 
diminished when compared to the control PC-3 cells.  These results can 
be accepted as the expression of Gapdh is constant in all lanes.  
Therefore to sum up these results, the PKA pathway has been 
established to play a role in the expression of NeuroD1, along with the 
mTOR pathway.  Again this highlights the multitude of roles that these 
signalling pathways undertake which the thesis focuses on which again 
are novel ideas.   
Neurogenin2 gene encodes for a helix-loop-helix transcriptional factor that 
can determine the neuronal fate on ectodermal cells.  They are 
indispensable to drive neuronal differentiation.  Moreover it is also 
expressed during the development of the central and peripheral nervous 
system in neural progenitor cells.  Both neurogenin2 and neuroD1 belong to 
the Atonal/Neurogenin family.  Neurogenin targets multiply genes needed 
for neurogenesis, and the overexpression of this protein has said to lead 
cells towards a neuronal lineage in Xenopus, chicks and rats (Murai et al., 
2011). NeuroD1 can be considered the central effector of Neurogenin’s 
function and in the Xenopus and mouse model has similar transcriptional 
targets.  Downstream signalling from the Notch receptor has been 
identified as the key pathway involved in maintaining the balance 
between progenitor safeguarding and progenitor differentiation.  Upon 
activation, Notch initiates its downstream effector, namely members of 
the Hes family, in particular Hes1 and Hes5 in mammals.  Members of 
this Hes family are negative regulators of neural differentiation as this 
demonstrated by overexpression of Hes1 in mice inhibited neuronal 
formation (Murai et al., 2011).  On the other hand, Hes6 works 
independently from notch signalling and is downstream of neuroD1 and 
induces neurogenesis once overexpressed in mice (Murai et al., 2011).  
Hes6 has said to bind to notch regulated Hes genes such as hes1, thus 
preventing its inhibitory effect, allowing neurogenesis to take place.  
Below illustrates a systematic view of the interaction of Notch, Hes1 and 
Hes6 in the involvement of neurogenesis. 
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Figure 13: Notch signalling causes the downstream activation of Hes1 
and this inhibits neurogenesis.  Hes6 is independent from Notch 
signalling and it is downstream of NeuroD1, interacts with Hes1 
disabling its inhibitory effect, allowing neurogenesis to take place.  
Third, the expression of DDC was assessed.  Figure 11 demonstrates 
that DDC is expressed in PC-3 cells, however when 10µM of H89 was 
administrated for 24 hours the band for DDC is reduced, again 
highlighting the importance of the PKA pathway in NED markers.  
However 1µM of Rapamycin did not produce a significant effect on the 
expression of DDC.  Perhaps the expression of DDC is independent of 
the PI3K pathway.  
DDC is considered a biomarker of neuroendocrine malignancies such as 
small-cell lung cancer and neuroblastoma.   It can also be used as a 
biomarker for PCa as it can predict shorter disease free survival intervals 
and relapse. The human L-DDC gene found on chromosome 7, encodes 
for a pyridoxal-phosphate dependent enzyme which catalyses the 
decarboxylation of L-DOPA to dopamine and also 5-HTP to serotonin 
(Geomela et al., 2012). Importantly, DDC is a co-activator of the 
androgen receptor by modulating the expression of AR regulated genes.  
DDC is involved in PCa cell proliferation under the influence of 
NOTCH 
SIGNALLING 
HES1 
NEUROGENESIS 
HES6 
HES1 
NEUROGENESIS 
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androgens by the means of catalysing the production of biogenic amines, 
which contributes to both proliferation and differentiation (Geomela et 
al., 2012).  This thesis therefore stresses that the successful inhibition of 
DDC by 10µM of H89 not only can hinder the onset of NED but can 
also hinder the proliferation of the cancer, which is of great significance.  
Below figure 14 summarised the mechanism by which the mentioned 
pathways and the different neuroendocrine markers interaction which 
this thesis has gathered data for.  
 
 
 
 
Figure 14:  The interaction of the signalling pathways and 
neuroendocrine markers. Activation of the JNK pathway leads to the 
onset of NSE expression, activation of the PKA pathway leads to onset 
of NSE, DDC and NeuroD1 expression, the activation of PI3K pathway 
leads to the onset of NSE expression.  Finally the mTOR pathway leads 
to the onset of NeuroD1 expression. 
4.8 Androgen dependence to androgen independence 
The initial intervention for PCa treatment is androgen ablation, however 
the downfall with this treatment occurs when the PCa cells transition 
from an androgen dependent state to androgen independent state.   This 
could be due to several mechanisms due to different signalling cascades 
that this thesis has focused on.  Firstly, PCa cells can survive in a low 
androgen environment by the means of AR amplification which leads to 
an improved occupied ligand receptor content. This is confirmed by 
30% of androgen independent tumours expressing an amplified AR 
gene, (Feldman and Feldman, 2001).   The survival of hormone 
refractory PCa cells through proliferation can be due to growth factors 
and the surrounding chemokine and cytokine milieu which can stimulate 
PKA PI3K mTOR JNK 
NSE DDC NeuroD1 
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the JNK, PI3K, PKA and mTOR pathway. This has been shown in the 
proliferation results whereby inhibition of the JNK, PI3K and mTOR 
pathway reduced the proliferation of two PCa cell lines.  Moreover, an 
increased sensitivity to low levels of DHT could also result in cancerous 
cells still being able to proliferate in castrated men.  Possibly the ability 
of PCa cells to convert testosterone to DHT by increasing the activity of 
5α-reductase could lead to local production of androgens needed for 
stable proliferation.   This was supported by the evidence that only 60% 
of DHT was reduced after androgen deprivation (Feldman and Feldman, 
2001).  
Some cases of castration resistant PCa have acquired gene mutations that 
can allow non-specific binding to the ligand binding domain of the AR 
causing malignant cells to thrive and avoid apoptosis.  Non-specific 
ligands comprise of oestrogen, progestins and anti-androgens such as 
flutamide.  It is thought throughout androgen ablation with the presence 
of a mutant AR can endure clonal expansion concurring a growth 
advantage.  What’s more, mutations can arise in the co-activators of the 
AR such as SRC1 and TIF2, when combined with AR mutations can 
lead to lethal AR activation (Feldman and Feldman, 2001). A vital 
signalling pathway that has been acknowledged for its role in PCa 
development is the PI3K/AKT/mTOR pathway.  The tumour 
suppressor gene PTEN is often found to be deregulated in PCa thus 
aberrant PI3K signalling progresses leading to over activation of Akt. 
Akt is known to disable pro-apoptotic proteins such as procaspase-9, 
thus apoptosis can be avoided.  Moreover Akt is known to 
phosphorylate over 50 substrates each involved in the hallmarks of 
carcinogenesis (Feldman and Feldman, 2001).  
4.9 Further research 
Firstly the protein expression of Wnt-11 and NSE need to be assessed 
with the addition of the mentioned inhibitors.  The reason being is most 
biological functions are carried out at a protein level rather than an 
mRNA level.  As most genes are regulated at a transcriptional level, 
other genes are involved with post transcriptional regulation processes 
such as the initiation of translation and the stability of proteins (Tian et 
al., 2004).  It is essential to understand the complexity of the changing 
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patterns amongst mRNA and how this correlates to their related protein.  
Therefore the western blot is an ideal technique to identify differences in 
protein expression under different cellular conditions. Moreover the 
phosphorylation status of the PI3K pathway should be assessed by either 
kinase activity assays or by the use of a phospho-specific antibody.   In 
terms of focusing on the PI3K pathway, several other components of 
the pathway need to be weighed.  For example the phosphorylation of 
Akt plays a heavy role in PCa progression and hormone independence.   
Moreover, invasion assays should be carried out to assess the ability of 
the mentioned inhibitors to destabilise the invasion capacity of PC-3 
cells. Q-PCR could be carried out to give quantitative results of gene 
expression as opposed to only visual data.   
4.10 Conclusion 
The research carried out during this thesis had the aims to identify the 
association with the expression of Wnt-11 with the JNK, PKA, PI3K 
and mTOR pathway and the effects this had on cellular proliferation, 
migration and gene expression. These aims were successfully achieved 
and an interaction between Wnt-11 and the mentioned pathways was 
identified which is novel and innovative. Moreover, the PI3K pathway 
had a definite role in aiding the migration of the PC-3 cells along with its 
proliferation which holds extreme importance especially with regards to 
PCa metastasis which causes the fatality of many patients.  All pathways 
were seen to take part in the expression of Wnt-11 and NSE collectively, 
which again is extremely significant as both markers are associated with 
aggressive and metastatic PCa.  
To conclude Wnt-11 has been evidenced to play a role in the 
progression, differentiation and hormone independence characteristics 
associated with malignant PCa. There are definite interlinks which have 
been preliminarily examined between the mentioned pathways and 
signals produced from these pathways which initiate the phenomenon of 
NED.  Wht-11 is therefore an ideal target for novel androgen 
independent PCa. Dual therapy will be more effective by targeting both 
Wnt-11 and one of the mentioned signalling pathways such as the PI3K 
pathway.  This underlines the essence of personalised treatment that is 
heavily needed for the near future to equip against rare cases of cancers 
and to stop unnecessary complications with non-specific PCa treatments.  
45 | P a g e  
 
References 
Amorino, G., Deeble, P. and Parsons, S. (2007). Neurotensin stimulates 
mitogenesis of prostate cancer cells through a novel c-SRC/Stat5b 
pathway. Oncogene 26: 745-756. 
Arcaro, A. and Guerreiro, A. (2007). The Phosphoinositide 3-Kinase 
Pathway in Human Cancer: Genetic Alterations and Therapeutic 
Implications. Curr. Genomics 5: 271-309.  
Bitting, R. and Armstrong, A. (2013).Targeting the PI3K/Akt/mTOR 
pathway in castration-resistant prostate cancer. Endocr. Relat. Cancer 20: 
83-96. 
Bode, A. and Dong, Z. (2010). The functional contrariety of JNK. Mol. 
Carcinog 8: 591-598.  
Caretta, A. and Caretta, C. (2011).Protein Kinase A in Cancer. Cancers 3: 
913-926. 
Chang, P., Wang, T., Chang, Y., Chu. C., Lee, C., Hsu, H., Zhou, T., Wu, 
Z., Kim, R., Desai, S., Liu, S. and Kung, K. (2014). Autophagy Pathway 
Is Required for IL-6 Induced Neuroendocrine Differentiation and 
Chemo-resistance of Prostate Cancer LNCaP Cells. Plos one 9: 1-15. 
Chen, S., Cai, C., Fisher, C., Zheng, Z., Omwancha, J., Hsieh, C. and 
Shemshedini, L. (2006). C-Jun enhancement of androgen receptor 
transactivation is associated with prostate cancer cell proliferation. 
Oncogene 25: 7212-7223.  
Deeble, P., Cox, M., Frierson, H., Sikes, R., Palmer, J., Davidson, R., 
Casarez, E., Amorino, G. and Parsons, S. (2007).  Androgen-
Independent Growth and Tumorigenesis of Prostate Cancer Cells Are 
Enhanced by the Presence of PKA-Differentiated Neuroendocrine Cells. 
Cancer Res 8: 3663-3672.  
Feldman, B. and Feldman, D. (2001).The development of androgen 
independent prostate cancer.Reviews Cancer 1: 34-45 
Feldman, M., Apsel, B., Uotila, A., Loewith, R., Knight, Z., Ruggero, D. 
and Shokat, K. (2009).  Active-site inhibitors of mTOR target of 
46 | P a g e  
 
rapamycin resistant outputs of mTORC1 and mTORC2.  PloS Biol 2: 
371-383.  
Garg, R., Blando, J., Perez, C., Wang, H., Benavides, F. and Kazanietz, 
M. (2012).Activation of Nuclear Factor κB (NF-κB) in Prostate Cancer 
Is Mediated by Protein Kinase C ϵ (PKCϵ). The journal of Biological 
Chemistry 287: 37570-37582.  
Geomela, P., Kontos, C., Yiotakis, I., Fragoulis, E. and Scorilas, A. 
(2012). L-DOPA decarboxylase mRNA expression is associated with 
tumour stage and size in head and neck squamous cell carcinoma: a 
retrospective cohort study. BMC Cancer 12: 1471-247.  
Girling, J., Whitaker, C. and Neal, D. (2007).Pathogenesis of prostate 
cancer and hormone refractory prostate cancer. Indian J Urol 1: 35-42. 
Guertin, D. and Sabatini, D. (2005).An expanding role for mTOR in 
cancer. TRENDS in Molecular Medicine 6: 1471-4921.  
Kenneth, P., Pienta, D., David, C. and Smith, M. (2009). Advances in 
Prostate Cancer Chemotherapy. A new era begins. Advances in Prostate 
Cancer Chemotherapy 55: 300-318. 
Kypta, R. and Waxman, J. (2012).Wnt/ β-catenin signalling in prostate 
cancer. Nature Reviews Urology 9: 418-428.  
Kypta, R. and Kawano, (2003). Secreted antagonists of the Wnt 
signalling pathway. J. Cell Sci 1: 2627-34.  
Lawson, D., Xin, L., Xu, Q., Cheng, D. and Witte, O. (2005). Prostate 
stem cells and prostate cancer.  Cold Spring Harb Symp Quant Biol (70): 
187-196. 
Lories, R., Corr, M. and Lane, N. (2013). To Wnt or not to Wnt: the 
bone and joint health dilemma. Nat.Rev.Rheumatol 9: 328-339. 
Luyten, F., Tylzanowski, P. and Lories, R. (2009).Wnt signalling and 
osteoarthritis.Bone. 44: 522-527.  
Makarov, D., Loeb, S., Getzenberg, R. and Partin, A. (2009). Biomarkers 
for Prostate Cancer. Annu.Rev.Med 60: 139-151. 
47 | P a g e  
 
Murai, K., Philpott, A. and Jones, P. (2011). Hes6 is required for the 
neurogenic activity of neurogenin and neuroD1. Plus one 11: e27880.  
Parri, M and Chiarugi, P. (2010).Rac and Rho GTPases in cancer cell 
motility control. Cell. Commun. Signal 8: 1-31. 
Roccaro, M,A., Sacco, A., Husu, E., Pitsillides, C., Vesole, S., Azab, A., 
Azab, F., Melhem, M., PhongQuang, H., Maiso, P., Runnels, J., Liang, 
M., Wong, K., Lin, C. and Ghobrial, I. (2010). Dual targeting of the 
PI3K/Akt/mTOR pathway as an antitumor strategy in 
Waldenstrommacroglobulinemia. Blood 115: 559-569.  
Rodriguez-Berriguete, G., Fraile, B., Martinez-Onsurbe, P., Olmedilla, 
G., Paniagua, R. and Royuela, m. (2011). MAP kinases and Prostate 
Cancer. Journal Signal Transduction 2012: 2-11. 
Saadeddin, A., Jadidi, R., Dene, B. and Nateri, A. (2009).The links 
between transcription, β-Catenin/JNK signalling and carcinogenesis. Mol 
Cancer. Res 7: 1189-1245.  
Sarker, D., Reid, A., Yap, T. and Bono, J. (2009).Targeting the 
PI3K/AKT Pathway for the Treatment of Prostate Cancer. Clin. Cancer. 
Res 15: 4799-4805.  
Schlessinger, K., Hall, A. and Tolwinski, N. (2009).  Wnt signalling 
pathways meet Rho GTPases.  Genes & Dev 23:265-277. 
Sun, Y., Niu, J. and Huang, J. (2009).Neuroendocrine differentiation in 
prostate cancer. Am. J. Transl. Res 2: 148-162.  
Tian, Q., Stepaniants, S., Mao, M., Weng, L., Feetham, M., Doyle, M., Yi, 
E., Dai, H., Thorsson, V., Eng, J., Goodlett, D., Berger, J., Gunter, B., 
Linseley, P., Stoughton, B., Aebersold, R., Collins, S., Hanlon, W. and 
Hood, L. (2004). Integrated Genomic and Proteomic Analyses of Gene 
Expression in Mammalian Cells. Molecular & Cellular Proteomics 3: 960-
969. 
Uysal-Onganer,P., Kawano, Y., Caro, M., Walker, M., Diez, S., 
Darrington, R., Waxman, J. and Kypta,R. (2010). Wnt-11 promotes 
neuroendocrine like differentiation, survival and migration of prostate 
cancer cells. Molecular Cancer 9:1186-1476. 
48 | P a g e  
 
Uysal-Onganer,P. and Kypta, R. (2012). Wnt-11 in 2011- the regulation 
and function of a non-canonical wnt. Acta. Physiol 204: 52-64. 
Wang, Y. (2009). Wnt/Planar cell polarity signalling. A new paradigm for 
cancer therapy.Molecular Cancer Therapeutics 8: 2103-2109.  
Wilt, J. and Ahmed, H. (2013). Prostate cancer screening and the 
management of clinically localised disease. BMJ 29: 325-346. 
Wu, C. and Huang, J. (2007). Phosphatidylinositol 3-Kinase-AKT-
Mammalian Target of Rapamycin Pathway Is Essential for 
Neuroendocrine Differentiation of Prostate cancer. The Journal of 
Biological Chemistry 282: 3571-3583.  
Yang.Y., Bost, Frederic, B., Charbono, W., Dean, N., McKay, R., Rhim, 
J., Depatie, C. and Mercola, D. (2003). C-Jun NH2 terminal kinase 
mediates proliferation and tumour growth of human prostate carcinoma. 
Clin. Cancer. Res 9: 140-156. 
Yuan, T. and Veeramani, S. and Lin, M. (2007). Neuroendocrine-like 
prostate cancer cells: neuroendocrine trans differentiation of prostate 
adenocarcinoma cells. Endocrine-Related Cancer 14: 531-547. 
Zhu, H., Mazor, M., Kawano, Y. , Walker, M., Leung, H., Armstrong, K.,  
Waxman, J. and Kypta, R. (2004). Analysis of Wnt gene expression in 
prostate cancer: Mutual inhibition by Wnt-11 and the androgen receptor. 
Cancer research 64: 7918-7926.  
 
* 
